FDA Clears Candela's Ellipse I2PL System for Skin Rejuvenation

Candela has received clearance from the FDA to market its next generation Ellipse I2PL system for skin rejuvenation of vascular and pigmented abnormalities.

The Ellipse successfully treats sun-damaged skin to reduce pigment and vascular disturbances by specifically heating targeted structures in the skin. It has a lightweight, ergonomically shaped handpiece that is easy to use and comfortable for both clients and operators.

The Ellipse allows effective treatments of large or small body areas and is the only intense pulsed light system to feature patented I2PL technology, which reduces the risk of side effects to the surrounding skin. Candela is distributing the Ellipse I2PL in the U.S. through a partnership with Danish Dermatologic Development.